Mitochondrial Reactive Oxygen Species (mROS) Generation and Cancer: Emerging Nanoparticle Therapeutic Approaches.

IF 6.6 2区医学 Q1 NANOSCIENCE & NANOTECHNOLOGY

International Journal of Nanomedicine Pub Date : 2025-05-13 eCollection Date: 2025-01-01 DOI:10.2147/IJN.S510972

Xinyao Wang, Xiangyang Xiong

引用次数: 0

Abstract

Mitochondrial reactive oxygen species (mROS) are generated as byproducts of mitochondrial oxidative phosphorylation. Changes in mROS levels are involved in tumorigenesis through their effects on cancer genome instability, sustained cancer cell survival, metabolic reprogramming, and tumor metastasis. Recent advances in nanotechnology offer a promising approach for precise regulation of mROS by either enhancing or depleting mROS generation. This review examines the association between dysregulated mROS levels and key cancer hallmarks. We also discuss the potential applications of mROS-targeted nanoparticles that artificially manipulate ROS levels in the mitochondria to achieve precise delivery of antitumor drugs.

查看原文本刊更多论文

线粒体活性氧（mROS）的产生和癌症：新兴的纳米颗粒治疗方法。

线粒体活性氧（mROS）是线粒体氧化磷酸化的副产物。mROS水平的变化通过其对癌症基因组不稳定性、癌细胞持续存活、代谢重编程和肿瘤转移的影响参与肿瘤发生。纳米技术的最新进展为通过增强或减少mROS的产生来精确调节mROS提供了一种很有前途的方法。这篇综述探讨了失调的mROS水平与关键癌症标志之间的关系。我们还讨论了靶向ROS的纳米颗粒的潜在应用，这些纳米颗粒可以人为地操纵线粒体中的ROS水平，以实现抗肿瘤药物的精确递送。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Nanomedicine NANOSCIENCE & NANOTECHNOLOGY-PHARMACOLOGY & PHARMACY

CiteScore

14.40

自引率

3.80%

发文量

511

审稿时长

1.4 months

期刊介绍： The International Journal of Nanomedicine is a globally recognized journal that focuses on the applications of nanotechnology in the biomedical field. It is a peer-reviewed and open-access publication that covers diverse aspects of this rapidly evolving research area. With its strong emphasis on the clinical potential of nanoparticles in disease diagnostics, prevention, and treatment, the journal aims to showcase cutting-edge research and development in the field. Starting from now, the International Journal of Nanomedicine will not accept meta-analyses for publication.